Autoantibody profiles associated with morbidity and mortality in scleroderma renal crisis.

Rheumatology (Oxford, England) Pub Date : 2022-10-06 DOI:10.1093/rheumatology/keac047

Hideaki Tsuji, Nobuo Kuramoto, Tsuneo Sasai, Mirei Shirakashi, Hideo Onizawa, Koji Kitagori, Shuji Akizuki, Ran Nakashima, Ryu Watanabe, Akira Onishi, Kosaku Murakami, Hajime Yoshifuji, Masao Tanaka, Motomu Hashimoto, Koichiro Ohmura, Akio Morinobu

{"title":"Autoantibody profiles associated with morbidity and mortality in scleroderma renal crisis.","authors":"Hideaki Tsuji, Nobuo Kuramoto, Tsuneo Sasai, Mirei Shirakashi, Hideo Onizawa, Koji Kitagori, Shuji Akizuki, Ran Nakashima, Ryu Watanabe, Akira Onishi, Kosaku Murakami, Hajime Yoshifuji, Masao Tanaka, Motomu Hashimoto, Koichiro Ohmura, Akio Morinobu","doi":"10.1093/rheumatology/keac047","DOIUrl":null,"url":null,"abstract":"Objective: The aim of this study was to investigate association of autoantibodies with scleroderma renal crisis (SRC) among Japanese patients.Methods: The clinical characteristics and mortality of 330 patients with sytemic screlosis (SSc) at Kyoto University Hospital were retrospectively analysed, focusing on possible association with anti-topoisomerase I (anti-topo I), anti-centromere (ACA), anti-RNA polymerase III (RNAPIII) and/or anti-U1-RNP. Logistic regression analyses were performed to reveal any association of these autoantibodies with the development and mortality of SRC.Results: SRC was observed in 24 out of 330 SSc patients, including patients with anti-topo I (n = 12/24, 50%), anti-RNAPIII (n = 7/24, 29%), anti-U1-RNP (n = 5/24, 21%) and ACA (n = 3/24, 13%). Anti-U1-RNP [odds ratio (95% CI), 3.63 (1.11, 10.2)], anti-topo I [3.22 (1.37, 7.57)] and anti-RNAPIII (3.29 [1.16, 8.70]) were associated with the development of SRC. Furthermore, anti-topo I [6.00 (1.11, 41.1)] was associated with 1-year mortality of SRC. The 1-year survival rate after the onset of SRC among all patients and among those positive for anti-topo I was 54% and 33%, respectively. In contrast, the survival rate in patients negative for anti-topo I was 75%, of which the survival rate of patients positive for anti-RNAPIII and ACA was 83% and 100%, respectively.Conclusion: Specific SSc-related autoantibodies were associated with the morbidity and mortality of SRC.","PeriodicalId":379078,"journal":{"name":"Rheumatology (Oxford, England)","volume":" ","pages":"4130-4135"},"PeriodicalIF":0.0000,"publicationDate":"2022-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Rheumatology (Oxford, England)","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/rheumatology/keac047","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 3

Abstract

Objective: The aim of this study was to investigate association of autoantibodies with scleroderma renal crisis (SRC) among Japanese patients.

Methods: The clinical characteristics and mortality of 330 patients with sytemic screlosis (SSc) at Kyoto University Hospital were retrospectively analysed, focusing on possible association with anti-topoisomerase I (anti-topo I), anti-centromere (ACA), anti-RNA polymerase III (RNAPIII) and/or anti-U1-RNP. Logistic regression analyses were performed to reveal any association of these autoantibodies with the development and mortality of SRC.

Results: SRC was observed in 24 out of 330 SSc patients, including patients with anti-topo I (n = 12/24, 50%), anti-RNAPIII (n = 7/24, 29%), anti-U1-RNP (n = 5/24, 21%) and ACA (n = 3/24, 13%). Anti-U1-RNP [odds ratio (95% CI), 3.63 (1.11, 10.2)], anti-topo I [3.22 (1.37, 7.57)] and anti-RNAPIII (3.29 [1.16, 8.70]) were associated with the development of SRC. Furthermore, anti-topo I [6.00 (1.11, 41.1)] was associated with 1-year mortality of SRC. The 1-year survival rate after the onset of SRC among all patients and among those positive for anti-topo I was 54% and 33%, respectively. In contrast, the survival rate in patients negative for anti-topo I was 75%, of which the survival rate of patients positive for anti-RNAPIII and ACA was 83% and 100%, respectively.

Conclusion: Specific SSc-related autoantibodies were associated with the morbidity and mortality of SRC.

查看原文本刊更多论文

自身抗体谱与硬皮病肾危象的发病率和死亡率相关。

目的:本研究的目的是探讨自身抗体与日本硬皮病肾危像(SRC)的关系。方法:回顾性分析京都大学医院330例全体性肝硬化(SSc)患者的临床特点和死亡率，重点分析其与抗拓扑异构酶I (anti-topo I)、抗着丝粒(ACA)、抗rna聚合酶III (RNAPIII)和/或抗u1 - rnp的关系。进行逻辑回归分析以揭示这些自身抗体与SRC的发展和死亡率之间的任何关联。结果:330例SSc患者中有24例出现SRC，包括抗topo I (n = 12/24, 50%)、抗rnapiii (n = 7/24, 29%)、抗u1 - rnp (n = 5/24, 21%)和ACA (n = 3/24, 13%)。抗u1 - rnp[比值比(95% CI)， 3.63(1.11, 10.2)]、抗topo I[3.22(1.37, 7.57)]和抗rnapiii(3.29[1.16, 8.70])与SRC的发生相关。此外，anti-topo I[6.00(1.11, 41.1)]与SRC的1年死亡率相关。所有患者和抗topo I阳性患者的SRC发病后1年生存率分别为54%和33%。相反，抗topo I阴性患者的生存率为75%，其中抗rnapiii和ACA阳性患者的生存率分别为83%和100%。结论:特异性SRC相关自身抗体与SRC的发病率和死亡率相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Rheumatology (Oxford, England)

自引率

0.00%

发文量